Milena Adamian is founder and executive of the Life Sciences Angel Network, which is focused on early-stage investing and entrepreneurial activities in medical devices and healthcare information technology and on the education of entrepreneurs and investors. 

Dr. Adamian brings the unique perspective of a clinician and academic researcher with genuine passion for breakthrough technologies enriched by industry knowledge, Wall Street, and venture capital experience. 

She spent last 20 years on various side of the medical device development. Her career included professional appointments at Interventional Cardiology department of Lenox Hill Hospital (NYC) and Columbus Hospital (Milan, Italy), Medical Director at Boston Scientific Corporation (NYSE:BSC), Equity analyst (Medical Devices and Supplies) at Lehman Brothers and Managing Director, Life Sciences, Easton Capital. 

Milena is actively involved in a number of accelerators and angel groups across the US. Milena’s past and present Board involvements include Xoft (now NYSE: ICAD), Cardiovascular Systems (now NYSE: CSII), Forge Medical, Precise Light Surgical, Quartzy, Comprehend Systems, VitaPortal (Russia). She is also an author of a number of scientific peer-reviewed papers and a frequent speaker at professional conferences. 

Dr. Adamian is a member of the American College of Cardiology. 

She holds an MSc degree in Biostatistics and Clinical Research Methods from Mailman School of Public Health at Columbia University, and MD and PhD degrees in Clinical Cardiology from the Russian Academy of Medical Sciences. 

Go to top


David Cassak been involved with the health care industry for more than 30 years and writes extensively on the medical device industry.  He is also a frequent speaker before various companies and industry trade groups.  For the five year period 2008-2013, Cassak served as VP Content and Managing Director, Medical Devices at Elsevier Business Intelligence.  Prior to  joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. 

Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other publications, including Start-Up: Emerging Medical Ventures,™ and The RPM Report: Regulation • Policy • Market Access.™ In 2004, Windhover acquired Medtech Insight Inc., publishers of the Medtech Insight: Medical Technology Market Intelligence™ newsletter.  In addition, Windhover alsocreated the Strategic Intelligence Systems, a web-based suite of databases, featuring the most comprehensive and detailed source of industry alliances, acquisitions and financings. SIS is unique among databases in providing expert commentary and analysis along with data.  Windhover/EBI also produced numerous conferences, including the Investment in Innovation (In3) medical device partnering conferences around the world, as well as such pharma-focused conferences as the Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover meetings.

In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and FDC Reports, publishers of The Gray Sheet and The Pink Sheet, among other leading industry newsletters. As noted, Cassak served as VP, Content and Managing Director, Medical Devices, for EBI.  Upon EBI’s 2014 sale to Informa, Cassak left and has launched a new publication, focused on the medical device industry,  with Steve Levin, a long-time colleague.

Go to top


Managing Director, Leerink Partners

Jed Cohen joined Leerink Partners as a Managing Director in 2009 to cover the medical technology sector. Jed has over 20 years of Healthcare Investment Banking experience, including 12 years at Citigroup and three years at UBS prior to joining Leerink. Jed’s transaction experience includes advisory work and financing assignments with clients across the healthcare industry, with an exclusive focus on “middle market” / emerging growth segments of the medical technology industry since 2000. He received a Bachelor of Science in Economics from the University of Pennsylvania’s Wharton School.

Go to top


Stacy Enxing Seng is an Executive-in-Residence for Covidien and a strategic adviser for the company’s $1.7 billion vascular therapies businesses. In these roles Stacy brings extensive experience in medical devices and technologies to help Covidien grow its global leadership in healthcare.
With more than two decades of operational leadership, she earlier served as president of Covidien’s Vascular Therapies division. Stacy joined Covidien in July 2010 through its acquisition of ev3, which she co-founded and led to become a $350 million business. She has also held positions with Boston Scientific, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. She received a bachelor’s degree from Michigan State University and a master’s degree in Business Administration from Harvard University.

Stacy serves on the board of directors for FIRE1, a med-tech company incubator based in Dublin, Ireland, and Solace Therapeutics, an emerging women’s health company based in Framingham, Massachusetts. In addition, she has been nominated to serve as a director of Zurich-based Sonova Holding AG, the world’s leading provider of hearing solutions. In 2013, Stacy was honored by Minneapolis/St. Paul Business Journal as one of Top 50 Women in Business.

Go to top  


Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering.

He is Professor in both the Departments of Medicine and Engineering at Stanford.  Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine.  He has led or participated in over 150 clinical trials, published over 450 manuscripts/chapters, and lectures worldwide. 

He has trained over 150 post-docs in Engineering and Medicine in the past decade.  In addition, he heads the Stanford/Asia MedTech innovation program.

Peter has been principle/founder of eighteen medical device companies in the San Francisco Bay Area. He has transitioned thirrteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, and co-founded TriVentures, which is an incubator/venture fund for early stage medical technology in Israel.

Go to top


Mr. Geoffrion carries with him 30 years of management experience in the medical device industry and more than 25 years specifically in the cardiovascular space.  Currently the CEO of Mitralign, a structural heart device company, he has previously led the company foundation, deal structuring and served as the early stage CEO for four medical device companies in addition to guiding the recapitalization and redirection of two additional successful medical device companies, all in the Cardiovascular space. 

Mr. Geoffrion currently serves on the Emerging Growth Company Council of Advamed and has also served as the Chairman of Impella CardioSystems AG, CircuLite, Inc. and FlowMedica, Inc.  He holds a BSME and an MBA from the University of Connecticut.

Go to top


Carla Kikken-Jussen, VP Medical Devices has over 30 years of experience in the medical device industry covering medical device clinical research and European Regulatory Affairs.

Carla’s industry experience includes her work with the Technical Committees and Working Groups of the European Commission in various areas: CEN-TC-316 “Animal tissues and their derivatives utilized in the manufacture of medical devices”; CEN-BT-WG 132 “Methods for analysis of Allergens” and  NEN-301-007 “Quality Systems for Body Materials”.
She served on the board of the Life Sciences Limburg Group and is a member of the Dutch Standardization Institute (NEN), the Regulatory Affairs Professional Society (RAPS) European Advisory Committee, the Orange County Regulatory Affairs organization, Member of the Board of Certification for CMDA (Certified Medical Device Associate) clinical evaluation, servers on the Advisory Board of GreenHills Ventures and is Chairperson of the Board of Vimecon GmbH.

In 2008 Carla was the first woman to be awarded the Entrepreneur of the Year by Rabobank Demarrage and in 2010 was awarded the Best Woman Entrepreneur by the Dutch Federation of Businesswomen.

Carla has been named one of the 100 most influential business women in The Netherlands by Next Women 100 for her contributions as a consultant in the medical technology field. In 2012 MediTech - the company she founded in 2000 -merged with Medpace to form a comprehensive global development group, conducting clinical research and regulatory affairs consultation for medical device.

Go to top


Stephen Levin has spent nearly 20 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide.  He and his long-time colleague, David Cassak, have just launched a new venture, Innovation In Medtech, which will feature a new medtech publication.  Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI), which was recently sold to Informa.  At EBI, he directed the editorial coverage for the company’s medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences. 

Levin became part of EBI when Elsevier acquired Windhover Information in 2008 and combined Windhover with FDC Reports to form the new group.  Levin had joined Windhover in 1997, where as Executive Editor, he supervised the editorial operations of IN VIVO, START-UP, and MEDTECH INSIGHT, while also covering the device industry, distribution, and legal issues.  He also served as the company’s General Counsel.  Prior to joining Windhover, Levin was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations, including the Whitewater inquiry.  Before joining the Subcommittee, Levin was an enforcement and regulatory attorney in the Federal Election Commission’s Office of General Counsel, and also worked at the US Department of Justice.  He was formerly an Editor of HEALTH INDUSTRY TODAY, a leading publication in the health care distribution industry.

Go to top


Co-Founder and CEO, Comprehend Systems

Rick is responsible for the overall direction and management of Comprehend Systems. In 2012, Rick was named to the PharmaVOICE 100, which recognizes the 100 most influential people in the life sciences industry.

Prior to Comprehend Systems, Rick spent nearly a decade developing clinical analytics tools, including tools used by the FDA and top pharmaceutical companies, at companies including Integrated Clinical Systems, where he led the design and implementation of several major new features.

Rick holds a bachelor’s degree in Computer Science from Carnegie Mellon University in Pittsburgh, Pennsylvania.

Go to top


Dr. Parhizgar is the President and Chief Executive Officer of Claret Medical Inc., the leader in development of embolic protection system during structural heart procedures. She is a Medtech industry senior executive and an entrepreneur. She has been serving as a non exec Director on a number of BODs, SABs, and CABs of private medtech and biotech companies.

In her last senior executive position as the Chief Operating Officer of Conor Medsystems, Inc. from 2004-2007, she led the successful $1.4B acquisition of the company by Johnson and Johnson Inc. in 2007.  Prior to her tenure at Conor Medsystems, from 1996- 2003 she was a senior executive vice president of Arterial Vascular Engineering Inc, which was acquired by Medtronic Corporation for $4.3B.  She held various executive vice president positions at Medtronic Corporation after the M&A.

Dr. Parhizgar received both her Ph.D. in Cell, Gene and Tissue Engineering and her M.Sc. in Biomechanical Engineering and Artificial Organ Design from Brown University, Providence, RI. graduating suma cum laude. Her scientific research was primarily concentrated on translational cardiovascular science specifically in the design of bioartificial miniaturized vascular grafts seeded with transfected progenitor cells.  She earned a dual major B.Sc. degree in pre-medicine biology/chemistry from Boston College, Boston, MA.

Go to top


Cheryl Pegus, M.D., M.P.H is President of Caluent, LLC, a healthcare advisory company supporting venture backed start-ups to public healthcare companies. She is a Director and Strategic Advisor of Glytec, a  glycemic clinical software organization, the Lead Independent Director of Vision Sciences, Inc. (VSCI) a leading provider of unique flexible endoscopic products and Director and Strategic Advisor of HealthFleet, an e-health company. Dr. Pegus is also the President of the American Heart Association (AHA) Founder’s Affiliate.

Previously she was the Chief Medical Officer for Walgreens, responsible for Clinical Affairs, Clinical Quality, Outcomes and Analytics, Employee Health and Wellness, and Clinical Sales.  Dr. Pegus has more than 20 years of clinical practice and industry experience.  She served as the General Manager and Chief Medical Officer for SymCare Personalized Health Solutions, Inc., a J&J start-up company, which provides innovative care management solutions utilizing remote monitoring, now part of the $2.6 billion J&J Diabetes Franchise. Prior to joining SymCare in 2007, she was the Head of Clinical Products for Aetna’s Medical Products Business Unit, responsible for developing, prioritizing and articulating the company’s clinical product strategy.  Former positions at Aetna include National Medical Director, Clinical Program Development/Design and Marketing for Aetna’s Member Advantage programs, and National Medical Director for Women’s Health.
Early in her career, she served as the Medical Director for the Cardiovascular Risk Factors Group at Pfizer Pharmaceuticals in New York.

She is a member of the board of directors of the Founder’s Affiliate of the American Heart Association.  In addition, Dr. Pegus is a member of the Dean’s Circle at Weill Cornell Medical College, sits on the editorial advisory board of Disease Management Advisor , was a Founding Board member of the National Business Group on Health’s  (NBGH) Obesity Taskforce and is a a past board member of the Care Continuum Alliance.

Dr. Pegus is a board-certified physician with subspecialty training in cardiology. She received an M.P.H. from Columbia University School of Public Health, an M.D. from Cornell University Medical College, completed her internal medicine residency and cardiology fellowship at New York Hospital-Cornell and practiced internal medicine and cardiology. She has published many peer-reviewed studies and  presented at national and inernational conferences.
She recently published the healthy cookbook, Everyone Eats.

Go to top


Mary Lake Polan, M.D., Ph.D., M.P.H., served as the chair of the Department of Obstetrics and Gynecology at the Stanford University School of Medicine and is currently an Adjunct Professor, Department of Obstetrics and Gynecology and Reproductive Sciences at Columbia University School of Medicine.

Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause.  She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine.  Dr. Polan received her M.P.H. (Maternal and Child Health Program) from the University of California, Berkeley.

Dr. Polan served on the board of Wyeth Pharmaceuticals prior to it’s acquisition by Pfizer and currently serves on the board of Quidel Corp, San Diego, CA  and on the boards of several privately held life sciences companies. She chairs an SAB in Women’s Health for the Proctor and Gamble Company and several other advisory boards of private life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies.

Dr. Polan’s research has involved ovarian and urologic function with many publications in both areas.  She is a member of the Institute of Medicine of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health.  She initiated The Eritrean Women’s Project in 2001 and has maintained this surgical project in Eritrea to repair fistulas resulting from traumatic births.

Go to top


Jon Salveson is the vice chairman of Piper Jaffray investment banking. Prior to his current position, Salveson was the global head of investment banking for seven years. He is involved in a full range of investment banking activities, including public and private equity and debt financings, M&A advisories and financial advisory services. Prior to leading the investment banking effort, Salveson spent his career at Piper Jaffray building a leading healthcare underwriting and M&A advisory practice. In 1996, Salveson opened the Piper Jaffray office in Menlo Park, Calif., where he was instrumental in establishing a large technology and healthcare presence in Silicon Valley, including over 100 investment banking and research professionals.

Prior to joining Piper Jaffray, Salveson was a product manager at a biotechnology firm.

Salveson graduated from St. Olaf College and received a Master of Management degree from the J.L. Kellogg Graduate School of Management at Northwestern University. He serves on the boards of CryoLife, Inc. (NYSE:  CRY) and Sunshine Heart, Inc. (NASDAQ:  SSH), and is a member of the board of the Minnesota Orchestra, and board of regents at St. Olaf College.

Go to top


Executive Vice President, Strategy & Corporate Development
As EVP, strategy and corporate development, Bryan is responsible for crafting Medidata's
corporate strategy, developing relationships with industry and financial communities, and driving
strategic partnerships, mergers and acquisition, joint ventures and other related transactions.

Previously, Bryan was a founding partner of the Technology Investment Banking Team at
Centerview Partners, where he was responsible for transaction evaluation, corporate strategy,
strategic positioning, and capital structure advisory. He’s also held leadership roles at the
Technology Investment Banking Groups at UBS Investment Bank and Bear Stearns.
Bryan holds an MBA from New York University Stern School of Business and a BA from the
University of Pennsylvania.

Go to top


Born in Brescia in 1966, Andrea Venturelli was in 1996 co-founder of Invatec (company active in the biomedical field), where he served as CEO & VP R&D from its foundation until acquisition by Medtronic Inc., in April 2010.Andrea grow Invatec from a start up of 5 employees to a company of 900 employees, more than 120M $ in revenue and presence in more than 70 country around the world
After the acquisition until April 2012, he remained a member of the senior staff of the new Medtronic CardioVascular Invatec, in the position of VP R & D and technical director.

In the past, Venturelli was founder and CEO of Vales, an industrial company specialized in the extrusion of techno-polymers for the automotive industry. This company was sold in 1996, when Venturelli and his partner Stefan Widensohler decided to found Invatec.
He was also CEO off Fogazzi srl, a company belonging to the Invatec group and acquired by Medtronic, which was specializes in the treatment of plastics and polymer technology.

Andrea Venturelli has ben member of the board of the Industrial Association of Brescia, section of Confindustria, and vice chairman of the board of directors of the chemical group of the same Association.

From February 2008 until April 2012 he has been member of the board of directors for the creation of centers of excellence and technology platforms within the CSMT - Service Centre Multisectorial and Technology (a technology center linked to the University) whose mission is to translate innovation into practice and allow ideas to become effective solutions through consulting, training, technology transfer and group synergy.

In 2005 he won the "Entrepreneur of the Year" by Apindustria, and in 2007 was nominated for "Entrepreneur of the Year" by Ernst & Young in the innovation category.

He led Invatec obtaining the "Excellence Award" conferred by Confindustria in 2006 and the "Prize for Economic Progress" of the Chamber of Commerce of Brescia (category companies sensitive to social issues) in 2008. In 2009, Invatec received the "National Award for Innovation" by the Presidency of the Council of Ministers, supported by the President of the Republic, and the award "Business Innovation" of Confindustria.

After he left Invatec ,Andrea Venturelli has diversified its activities in the areas of renewable energy (shareholder , CEO and member of the board of three companies involved in the generation of solar energy), in the field of real estate with a focus in Manhattan and the hospitality. Andrea Venturelli is member of the LSAN (Life Science Angel Network), a group of angel investors based in NYC focus on Life Sciences investments and Venture Partner in Innogest , an Italian Private Equity focus on medical device and IT . He is also shareholder and board member of Nobil Bioricerche , an Italian company active is the biomedical field.

Go to top


Ashley Wallin is the Executive Director and Vice President for AdvaMed’s Emerging Growth Company Council (EGCC).  In this role, she represents the interests of the Association’s emerging and early-growth enterprises and focuses on facilitating a policy environment conducive to capital formation and innovation, advocating for domestic and international payment and regulatory policies that are favorable to emerging companies, and providing educational opportunities for industry leaders and professionals in this entrepreneurial sector.
Prior to joining AdvaMed in early 2012, Ashley spent nearly ten years working in the med tech and pharmaceutical industries with a focus on product development, commercialization strategy, and operations – working with both small, venture-backed enterprises and large corporations, including Eli Lilly and Medtronic.

Wallin received a master’s degree in bioengineering and a bachelor’s degree in mechanical engineering from the Georgia Institute of Technology, and a Master of Business Administration from the University of Virginia’s Darden School of Business.

Go to top


Jaime Wheeler is the Senior Director, Global Clinical Affairs for Stryker Neurovascular.  She is an accomplished, strategic leader with progressive organizational and operational management experience in clinical affairs, strategic planning, mergers and acquisitions and transformational change.  Ms. Wheeler has been involved in both due diligence activities for several medical device companies and subsequent remediation and Integration activities for three major deals (Stryker 2010, Concentric Medical 2011, Surpass Ltd. 2012) including technology transfers, electronic system creation, quality system integration and transformational change while simultaneously overseeing the conduct and completion of ongoing day-to-day global clinical research activities and programs.  Prior to her role at Stryker Neurovascular, Ms. Wheeler served as the Director of Clinical Affairs, Boston Scientific Japan K.K. in Tokyo, Japan where she was responsible for the strategy and conduct of in-country clinical research activities and foreign clinical data submissions to the Ministry of Health, Labor, and Welfare - Pharmaceutical and Medical Devices Agency.    

Ms. Wheeler received her Bachelor of Science degree from Virginia Tech and her Master of Business Administration from Florida Atlantic University.

Go to top

LSAN® 2014